160 related articles for article (PubMed ID: 11888936)
1. Nucleophosmin-anaplastic lymphoma kinase (NPM-ALK), a novel Hsp90-client tyrosine kinase: down-regulation of NPM-ALK expression and tyrosine phosphorylation in ALK(+) CD30(+) lymphoma cells by the Hsp90 antagonist 17-allylamino,17-demethoxygeldanamycin.
Bonvini P; Gastaldi T; Falini B; Rosolen A
Cancer Res; 2002 Mar; 62(5):1559-66. PubMed ID: 11888936
[TBL] [Abstract][Full Text] [Related]
2. Antiangiogenic properties of 17-(dimethylaminoethylamino)-17-demethoxygeldanamycin: an orally bioavailable heat shock protein 90 modulator.
Kaur G; Belotti D; Burger AM; Fisher-Nielson K; Borsotti P; Riccardi E; Thillainathan J; Hollingshead M; Sausville EA; Giavazzi R
Clin Cancer Res; 2004 Jul; 10(14):4813-21. PubMed ID: 15269157
[TBL] [Abstract][Full Text] [Related]
3. EBP2, a novel NPM-ALK-interacting protein in the nucleolus, contributes to the proliferation of ALCL cells by regulating tumor suppressor p53.
Uchihara Y; Tago K; Tamura H; Funakoshi-Tago M
Mol Oncol; 2021 Jan; 15(1):167-194. PubMed ID: 33040459
[TBL] [Abstract][Full Text] [Related]
4. Recombinant expression, characterization, and quantification in human cancer cell lines of the Anaplastic Large-Cell Lymphoma-characteristic NPM-ALK fusion protein.
Kourentzi K; Crum M; Patil U; Prebisch A; Chavan D; Vu B; Zeng Z; Litvinov D; Zu Y; Willson RC
Sci Rep; 2020 Mar; 10(1):5078. PubMed ID: 32193476
[TBL] [Abstract][Full Text] [Related]
5. The acetylation of STAT3 at K685 attenuates NPM-ALK-induced tumorigenesis.
Korai A; Lin X; Tago K; Funakoshi-Tago M
Cell Signal; 2024 Feb; 114():110985. PubMed ID: 38000524
[TBL] [Abstract][Full Text] [Related]
6. Interleukin-9 (IL-9) and NPM-ALK each generate mast cell hyperplasia as single 'hit' and cooperate in producing a mastocytosis-like disease in mice.
Merz H; Kaehler C; Hoefig KP; Branke B; Uckert W; Nadrowitz R; Cerny-Reiterer S; Herrmann H; Feller AC; Valent P
Oncotarget; 2010 Jun; 1(2):104-119. PubMed ID: 21297223
[TBL] [Abstract][Full Text] [Related]
7. The Major Heat Shock Proteins, Hsp70 and Hsp90, in 2-Methoxyestradiol-Mediated Osteosarcoma Cell Death Model.
Gorska-Ponikowska M; Kuban-Jankowska A; Marino Gammazza A; Daca A; Wierzbicka JM; Zmijewski MA; Luu HH; Wozniak M; Cappello F
Int J Mol Sci; 2020 Jan; 21(2):. PubMed ID: 31963524
[TBL] [Abstract][Full Text] [Related]
8. NPM-ALK Is a Key Regulator of the Oncoprotein FOXM1 in ALK-Positive Anaplastic Large Cell Lymphoma.
Haque M; Li J; Huang YH; Almowaled M; Barger CJ; Karpf AR; Wang P; Chen W; Turner SD; Lai R
Cancers (Basel); 2019 Aug; 11(8):. PubMed ID: 31390744
[TBL] [Abstract][Full Text] [Related]
9. Gambogic acid, a natural product inhibitor of Hsp90.
Davenport J; Manjarrez JR; Peterson L; Krumm B; Blagg BS; Matts RL
J Nat Prod; 2011 May; 74(5):1085-92. PubMed ID: 21486005
[TBL] [Abstract][Full Text] [Related]
10. V600E B-Raf requires the Hsp90 chaperone for stability and is degraded in response to Hsp90 inhibitors.
Grbovic OM; Basso AD; Sawai A; Ye Q; Friedlander P; Solit D; Rosen N
Proc Natl Acad Sci U S A; 2006 Jan; 103(1):57-62. PubMed ID: 16371460
[TBL] [Abstract][Full Text] [Related]
11. ALK receptor activation, ligands and therapeutic targeting in glioblastoma and in other cancers.
Wellstein A
Front Oncol; 2012; 2():192. PubMed ID: 23267434
[TBL] [Abstract][Full Text] [Related]
12. Degradable Cross-Linked Nanoassemblies as Drug Carriers for Heat Shock Protein 90 Inhibitor 17-N-Allylamino-17-demethoxy-geldanamycin.
Ponta A; Akter S; Bae Y
Pharmaceuticals (Basel); 2011 Sep; 4(10):1281-1292. PubMed ID: 27721325
[TBL] [Abstract][Full Text] [Related]
13. NPM-ALK fusion kinase of anaplastic large-cell lymphoma regulates survival and proliferative signaling through modulation of FOXO3a.
Gu TL; Tothova Z; Scheijen B; Griffin JD; Gilliland DG; Sternberg DW
Blood; 2004 Jun; 103(12):4622-9. PubMed ID: 14962911
[TBL] [Abstract][Full Text] [Related]
14. Fusion of a kinase gene, ALK, to a nucleolar protein gene, NPM, in non-Hodgkin's lymphoma.
Morris SW; Kirstein MN; Valentine MB; Dittmer KG; Shapiro DN; Saltman DL; Look AT
Science; 1994 Mar; 263(5151):1281-4. PubMed ID: 8122112
[TBL] [Abstract][Full Text] [Related]
15. Ubiquitination and proteasomal degradation of nucleophosmin-anaplastic lymphoma kinase induced by 17-allylamino-demethoxygeldanamycin: role of the co-chaperone carboxyl heat shock protein 70-interacting protein.
Bonvini P; Dalla Rosa H; Vignes N; Rosolen A
Cancer Res; 2004 May; 64(9):3256-64. PubMed ID: 15126367
[TBL] [Abstract][Full Text] [Related]
16. Increased Tenascin C, Osteopontin and HSP90 Levels in Plasmatic Small Extracellular Vesicles of Pediatric ALK-Positive Anaplastic Large Cell Lymphoma: New Prognostic Biomarkers?
Lovisa F; Garbin A; Crotti S; Di Battista P; Gallingani I; Damanti CC; Tosato A; Carraro E; Pillon M; Mafakheri E; Romanato F; Gaffo E; Biffi A; Bortoluzzi S; Agostini M; Mussolin L
Diagnostics (Basel); 2021 Feb; 11(2):. PubMed ID: 33562105
[TBL] [Abstract][Full Text] [Related]
17. NPM-ALK: A Driver of Lymphoma Pathogenesis and a Therapeutic Target.
Andraos E; Dignac J; Meggetto F
Cancers (Basel); 2021 Jan; 13(1):. PubMed ID: 33466277
[TBL] [Abstract][Full Text] [Related]
18. CDC37 as a novel target for the treatment of NPM1-ALK expressing anaplastic large cell lymphomas.
Kuravi S; Parrott E; Mudduluru G; Cheng J; Ganguly S; Saunthararajah Y; Jensen RA; Blagg BS; McGuirk JP; Balusu R
Blood Cancer J; 2019 Jan; 9(2):14. PubMed ID: 30696805
[No Abstract] [Full Text] [Related]
19. Anaplastic lymphoma kinase fusions: Roles in cancer and therapeutic perspectives.
Cao Z; Gao Q; Fu M; Ni N; Pei Y; Ou WB
Oncol Lett; 2019 Feb; 17(2):2020-2030. PubMed ID: 30675269
[TBL] [Abstract][Full Text] [Related]
20. EBNA1-targeted inhibitors: Novel approaches for the treatment of Epstein-Barr virus-associated cancers.
Jiang L; Xie C; Lung HL; Lo KW; Law GL; Mak NK; Wong KL
Theranostics; 2018; 8(19):5307-5319. PubMed ID: 30555548
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
